Clario Strengths, Domain Expertise, and Key Differentiators
Clario is a technology firm dedicated to advancing clinical research by merging scientific proficiency with global reach to develop the most comprehensive endpoint technology platform. Through this, Clario enables its collaborators to effect transformative changes in healthcare. Driven by a commitment to technological innovation, Clario aims to shape the future of clinical trials and contribute positively to global healthcare outcomes.
Clario Recent Developments
In September 2023, Clario introduced Clario Oncology Trial Solutions, offering the most comprehensive array of endpoint collection technologies in the industry. This portfolio is meticulously crafted to address the evolving needs of modern oncology clinical development programs, prioritizing efficacy, safety, and quality of life enhancements aimed at transforming lives.
In March 2023, Clario unveiled its Federated Identity Management (FIM) System, designed to offer a seamless and secure authentication solution for its leading clinical trial platform. FIM streamlines access to online resources and services by enabling users to utilize the same login credentials across various systems and organizations. This eliminates the need for multiple usernames and passwords, enhancing user convenience while bolstering security by minimizing the proliferation of accounts and passwords.
In March 2023, Clario introduced a state-of-the-art cloud-based Image Viewer tool tailored for sponsors and CROs engaged in clinical trials. This innovative tool grants users access to read-quality images almost instantaneously through an intuitive web-based interface. By automating manual steps, it simplifies image accessibility while ensuring security. Equipped with viewing and manipulation capabilities for full-resolution images, users can derive valuable insights from trial subjects. Moreover, the tool adheres to data privacy regulations, facilitating seamless electronic image access within a fully integrated platform.
In June 2021, Clario introduced iSpiro Virtual Visits, a platform enabling live coaching during at-home pulmonary function tests (PFT). This innovation underscores Clario's dedication to customer-centric solutions and decentralization in healthcare delivery.
Clario Mergers and Acquisitions (M&A) Activities
In November 2021, ERT, a global leader in clinical trial endpoint technology, announced its merger with Bioclinica, a renowned leader in medical imaging technology and science, resulting in the formation of a unified entity named Clario.
Clario Customers in ARTW Customer Database
Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying Clario applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of Clario and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified eCOA Clinical Trials, Clario Source Document Manager customers.
Clario Overview
1818 Market St. Suite 2600
Philadelphia, PA, 19103, United States
1 215-972-0420
https://www.clario.com/
Ownership: - x
Number of Employees: 7200
Functional Markets: Analytics and BI, Content Management, ERP Services and Operations,
Key Verticals: Healthcare, Life Sciences,
Clario Key Enterprise and Cloud Applications
eCOA Clinical Trials, Clario Source Document Manager
Clario Revenues, $M:
| Type/Year | 2022 | 2023 | YoY Growth, % |
|---|---|---|---|
| Total Revenues, $M | Subscribe | Subscribe | Subscribe |
| Enterprise Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
| Cloud Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
* Enterprise Applications Revenues = License + Support & Maintenance + SaaS
** All revenue figures are estimates based on public records, Cloud and Non-Cloud business models in Apps Run The World's vendor database, and annual survey results including vendor feedback.
Clario Revenue Breakdown By Type, $M:
Clario Enterprise Applications Revenues By Functional Markets, $M:
Clario Enterprise Applications Revenues By Verticals, $M:
Clario Revenues By Region, $M
| Region | % of Total Revenues | 2023 Total Revenues, $M | 2023 Enterprise Applications Revenues, $M | 2023 Cloud Applications Revenues, $M |
|---|---|---|---|---|
| Americas | Subscribe | Subscribe | Subscribe | Subscribe |
| EMEA | Subscribe | Subscribe | Subscribe | Subscribe |
| APAC | Subscribe | Subscribe | Subscribe | Subscribe |
| Total | Subscribe | Subscribe | Subscribe | Subscribe |
Clario Direct vs Indirect sales
| Region | Direct Sales | Indirect Sales | Total |
|---|---|---|---|
| Type % | Subscribe | Subscribe | Subscribe |
| Revenues, $M | Subscribe | Subscribe | Subscribe |
Clario Customers - Breakdown by Geo, Size, Vertical and Product
List of Verified Clario Customers
No. of Clario Customers: 770
No. of Clario Enterprise Applications Customers: x
No. of Clario Cloud Customers: x
No. of Clario Cloud Subscribers: x
Clario boasts a client base exceeding 770, inclusive of the top 20 pharmaceutical and biotech companies worldwide. Notable clients include Pfizer, ClinPlan, Millennium Pharmaceuticals, Luitpold Pharmaceuticals, and numerous others.
Clario Market Opportunities, M&A and Geo Expansions
In July 2023, Clario welcomed Jason Knoblauch as its new Chief Financial Officer, alongside three internal promotions to the Executive Leadership Team: Lauren Misztal to Senior Vice President, General Counsel; Dr. Joyce Suhy to Executive Vice President, Medical Imaging and Specialty Solutions; and Kristina Lowe to Senior Vice President, Client Success and Customer Experience. These appointments signify Clario's commitment to bolstering growth, enhancing customer service, and fostering scientific innovation and expertise.
The merger of ERT Clinical and BioClinica represents a fusion of decades of scientific expertise and unparalleled global reach, establishing Clario as a comprehensive endpoint technology platform. Positioned to streamline the clinical trial process, enhance trial experiences, and unlock composite endpoints, Clario transcends the mere amalgamation of two companies.
Clario Risks and Challenges
In August 2023, Clario disclosed the divestiture of its Software Solutions business, an all-encompassing offering designed to facilitate the clinical trial lifecycle. The suite, known as Clario eClinical (comprising CTMS, eConsent, EDC, RTSM/IRT, Patient, and Site Payments), will undergo rebranding and integration into the established Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing innovative Clinical solutions for new customers as well.
Heightened consolidation within the pharmaceutical industry may impede BioClinica's future growth trajectory. Moreover, shifts in senior leadership could prompt alterations in both product development strategies and business operations.
Clario Ecosystem, Partners, Resellers and SI
In October 2023, Clario unveiled a strategic collaboration with Trial Data, a prominent decentralized clinical trial (DCT) service provider. This partnership aims to introduce cutting-edge decentralized clinical trial solutions to the Chinese market and promote patient-centric clinical trials in China.
In September 2023, Clario forged a partnership with CellCarta to revolutionize clinical trial sample management, particularly in histopathology studies. Through this strategic collaboration, Clario integrates CellCarta's expertise into its web-based platform, ensuring compliance with 21 CFR Part 11 standards. This joint effort aims to optimize the handling and digitization of tissue and biopsy samples across various therapeutic domains, thereby enhancing accessibility for pathology-focused trials. By offering a comprehensive solution for imaging and pathology within clinical trials, it facilitates end-to-end visibility in sample management, automates the transfer of digitized pathology images, and expedites centralized assessments.
In August 2023, Dr. Vince Clinical Research (DVCR), an early-phase Clinical Research Organization (CRO), revealed a new collaboration with Clario. This partnership aims to broaden access to Clario’s well-established Early Precision QT (EPQT) methodology. Often, this data proves adequate for meeting the International Council for Harmonization (ICH) E14 regulatory standards, potentially enabling Sponsor companies to qualify for a Thorough QT study waiver. Through this alliance, Dr. Vince Clinical Research and Clario aspire to enable more biopharmaceutical firms to acquire precise and cost-effective cardiac safety data at an earlier stage of the clinical development journey.
In August 2023, Clario unveiled an extended collaboration with AliveCor, a prominent leader in FDA-cleared personal electrocardiogram (ECG) technology. Together, Clario and AliveCor have joined forces to introduce advanced six-lead ECG solutions tailored for monitoring in decentralized clinical trials. This collaboration introduces state-of-the-art ECG technology to trial participants' homes, facilitating precise cardiac safety trial measurements with reduced reliance on site visits.
In March 2023, Clario collaborated with GI Reviewers, esteemed Gastroenterology consultants and central readers, alongside RSIP Vision, a leading developer of cutting-edge AI technologies for medical imaging, to introduce an innovative AI-based scoring system for inflammatory bowel diseases. This solution aims to enhance the consistency of colonoscopy video scoring, streamline workflow by reducing the time needed for human expert readers to score, and ultimately enhance recruitment while decreasing costs associated with clinical trials.
In March 2023, Clario unveiled a collaboration with technology startup ArtiQ aimed at bolstering confidence in respiratory clinical trials reliant on spirometry data. This partnership facilitates access to AI-based spirometry data reviews within the Clario platform for clinical trial purposes.
Clario cultivates diverse Strategic Partnerships aligned with our vision and best practices to address customer needs effectively. These partnerships encompass marketing, technical, and co-development collaborations aimed at achieving mutual objectives. Among Clario's Partners are AliveCor, Cogstate, ActiGraph, MedSource, MMS Holdings, PRL Central Laboratory Services, Health Sciences International, Novella Clinical, Axio Research, Beardsworth, Kaizen Clinical Services, Symbiance, and several others.
Clario Cloud Infrastructure Insights
Subscribe to read more about:
- Clario Public Cloud and Infrastructure (IaaS)
- Clario Platform (PaaS)
- Clario Application Delivery
- Clario Private Cloud and Data Centers
Research Methodology
Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.
Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).
For additional information on our methodologies, here's the link:
https://www.appsruntheworld.com/About Ushttps://www.appsruntheworld.com/taxonomy
https://www.appsruntheworld.com/FAQ
